MAOB and drug-induced dyskinesia: The lower use of dopamine agonist monotherapy in PRISM may reflect changes in treatment recommendations and prescribing practice over time, since dopamine agonists and MAO-B inhibitors were preferred over levodopa as initial monotherapy options 25 years ago because of their perceived potential to delay the onset of dyskinesia and/or motor fluctuations, and a misplaced notion that they were neuroprotective [28].